On June 8, 2026, the U.S. Food and Drug Administration (FDA) cleared 4TEEN4's Investigational New Drug (IND) application for invobenitug. The IND clearance marks a key regulatory milestone and allows 4TEEN4 to proceed with its planned clinical studies.
Our Investors
